跳到正文
原文
Endpoints News 生物医药· Anna Brown·· 2 小时前AI 评分25

Celldex 停止eczema治疗药物barzolvolimab的临床试验

Celldex culls eczema study after Phase 2 failure

AI 导读

Celldex Therapeutics 停止了其单克隆抗体药物barzolvolimab用于治疗eczema的临床试验,该药物在中期试验中失败。

正文

Celldex Ther­a­peu­tics is drop­ping its mon­o­clon­al an­ti­body as a ther­a­py for eczema af­ter the drug flunked a mid-stage study.

The drug, called bar­zolvolimab, failed to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news